HYPERLIPIDEMIA AGENTS
PRIOR AUTHORIZATION REQUEST
PRESCRIBER FAX FORM

ONLY the prescriber may complete and fax this form. This form is for prospective, concurrent, and retrospective reviews.

Incomplete forms will be returned for additional information. The following documentation is required for prior authorization consideration. For formulary information and to download additional forms, please visit https://www.bcbstx.com/provider/medicaid/pharmacy/rx-prior-auth

PATIENT AND INSURANCE INFORMATION **Today's Date:** _____

Patient Name (First):	Last:	M:	DOB (mm/dd/yy):
Patient Address:	City, State, Zip:	Patient Telephone:	
BCBSTX ID Number:	Group Number:		

PRESCRIBER/CLINIC INFORMATION

Prescriber Name:	Prescriber NPI#:	Specialty:	Contact Name:
Clinic Name:	Clinic Address:		
City, State, Zip:	Phone #:	Secure Fax #:	

PLEASE ATTACH ANY ADDITIONAL INFORMATION THAT SHOULD BE CONSIDERED WITH THIS REQUEST

Patient's Diagnosis (please check one of the following):

☐ Diagnosis of Heterozygous Familial Hypercholesteremia Date of diagnosis:_____

☐ Clinical Atherosclerotic Cardiovascular Disease Date of diagnosis:_____

☐ Diagnosis of Homozygous Familial Hypercholesteremia Date of diagnosis:_____

☐ Diagnosis of Primary Hyperlipidemia Date of diagnosis:_____

☐ Other, please specify ICD code plus description _____ Date of diagnosis:_____

Medication Requested: Strength:

Dosing Schedule: Quantity per Month:

Please indicate PSCK9 Treatment Status: ☐ Initial ☐ Continuation; Date of treatment initiation: _____

☐ Expedited/Urgent Review Requested: By checking this box and signing below, I certify that applying the standard review time frame may seriously jeopardize the life or health of the patient or the patient's ability to regain maximum function.

Signature of prescriber or prescriber's designee: _____ Date: _____

Section 1. Drug Treatment History (complete as applicable):

Drug	**Last prescribed dose**	**Start date** (mm/dd/ccyy)	**End date*** (if applicable) (mm/dd/ccyy or N/A)
☐ atorvastatin			
☐ ezetimibe			
☐ rosuvastatin			
☐ other (please specify):			
☐ other (please specify):			
☐ other (please specify):			

**For current therapy, indicate "N/A" for "End date".*

Please continue to next page.

Patient Name (First):	Last:	M:	DOB (mm/dd/yy):

1. Is the patient currently treated with the requested medication? ☐ Yes ☐ No
   If yes, when was treatment with the requested medication started: _____
   If yes, has the patient shown clinical response since initiating therapy? ☐ Yes ☐ No
2. Is the patient currently pregnant? ☐ Yes ☐ No
3. Does the patient have a diagnosis of moderate or severe hepatic impairment in the last 365 days? ☐ Yes ☐ No
4. Has the patient tried 90 days of atorvastatin? ☐ Yes ☐ No
5. Has the patient tried 90 days of rosuvastatin? ☐ Yes ☐ No
6. Has the patient tried 90 days of treatment with ezetimibe concurrently with atorvastatin or rosuvastatin, immediately prior to PCSK9 inhibitor PA request? ☐ Yes ☐ No
7. Is the low density lipoprotein-cholesterol (LDL-C) level >70mg/dl despite treatment with 90 days of atorvastatin treatment, 90 days of rosuvastatin, and most recently, 90 days of ezetimibe treatment? ☐ Yes ☐ No

Section 2. Laboratory Information:

LDL-C prior to initiation of PCSK9 treatment: _____ mg/dL	Date level obtained: _____ (for first time requests, level must be from previous 60 days)
Current LDL-C: _____ mg/dL*	Date level obtained: _____ (level must be from previous 60 days)

*Required for renewal requests only. Must have at least a 50% reduction in LDL-C compared to LDL-C level prior to PCSK9 treatment initiation for patients with HeFH and at least a 30% reduction in LDL-C for patients with HoFH for renewal approval.

By signing below, I, the prescriber, certify that the information provided above is verifiable and accurate to the best of my knowledge.

Prescriber Signature: _____ Date: _____

Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions. The submitting provider certifies that the information provided is true, accurate, and complete and the requested services are medically indicated and necessary to the health of the patient.

Note: Payment is subject to member eligibility. Authorization does not guarantee payment.

Please fax or mail this form to:
Prime Therapeutics LLC, Clinical Review Department
2900 Ames Crossing Road
Eagan, Minnesota 55121

TOLL FREE
Fax: 877.243.6930 Phone: 855.457.0407

CONFIDENTIALITY NOTICE: This communication is intended only for the use of the individual entity to which it is addressed and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 866.202.3474 and return the original message to Prime Therapeutics via U.S. Mail. Thank you for your cooperation.